263 related articles for article (PubMed ID: 34059941)
21. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
Paul T; Mondal A; Bandyopadhyay TK
Recent Pat Biotechnol; 2019; 13(1):33-44. PubMed ID: 30318009
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic l-asparaginase: upstream, downstream and beyond.
Lopes AM; Oliveira-Nascimento L; Ribeiro A; Tairum CA; Breyer CA; Oliveira MA; Monteiro G; Souza-Motta CM; Magalhães PO; Avendaño JG; Cavaco-Paulo AM; Mazzola PG; Rangel-Yagui CO; Sette LD; Converti A; Pessoa A
Crit Rev Biotechnol; 2017 Feb; 37(1):82-99. PubMed ID: 26694875
[TBL] [Abstract][Full Text] [Related]
23. Endophytic Fungi as a Promising Source of Anticancer L-Asparaginase: A Review.
Parashiva J; Nuthan BR; Rakshith D; Satish S
Curr Microbiol; 2023 Jul; 80(9):282. PubMed ID: 37450223
[TBL] [Abstract][Full Text] [Related]
24. Extracellular expression of
Biasoto HP; Hebeda CB; Farsky SHP; Pessoa A; Costa-Silva TA; Monteiro G
Prep Biochem Biotechnol; 2023; 53(5):511-522. PubMed ID: 35981094
[TBL] [Abstract][Full Text] [Related]
25. Recent Strategies and Applications for l-Asparaginase Confinement.
Nunes JCF; Cristóvão RO; Freire MG; Santos-Ebinuma VC; Faria JL; Silva CG; Tavares APM
Molecules; 2020 Dec; 25(24):. PubMed ID: 33321857
[TBL] [Abstract][Full Text] [Related]
26. Biochemical characterization of glutaminase-free L-asparaginases from Himalayan Pseudomonas and Rahnella spp. for acrylamide mitigation.
Patial V; Kumar S; Joshi R; Singh D
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128576. PubMed ID: 38048933
[TBL] [Abstract][Full Text] [Related]
27. Aliivibrio fischeri L-Asparaginase production by engineered Bacillus subtilis: a potential new biopharmaceutical.
Bento HBS; Paiva GB; Almeida MR; Silva CG; Carvalho PJ; Tavares APM; Pedrolli DB; Santos-Ebinuma VC
Bioprocess Biosyst Eng; 2022 Oct; 45(10):1635-1644. PubMed ID: 35974197
[TBL] [Abstract][Full Text] [Related]
28. Towards development of biobetter: L-asparaginase a case study.
Tripathy RK; Anakha J; Pande AH
Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130499. PubMed ID: 37914146
[TBL] [Abstract][Full Text] [Related]
29. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.
Kotzia GA; Labrou NE
J Biotechnol; 2007 Jan; 127(4):657-69. PubMed ID: 16984804
[TBL] [Abstract][Full Text] [Related]
30. Current applications and different approaches for microbial l-asparaginase production.
Cachumba JJ; Antunes FA; Peres GF; Brumano LP; Santos JC; Da Silva SS
Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):77-85. PubMed ID: 27866936
[TBL] [Abstract][Full Text] [Related]
31. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
[TBL] [Abstract][Full Text] [Related]
32. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of recent trends in research on therapeutically significant L-asparaginase and acute lymphoblastic leukemia.
Suresh SA; Ethiraj S; Rajnish KN
Mol Biol Rep; 2022 Dec; 49(12):11281-11287. PubMed ID: 35816224
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
35. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
Costa-Silva TA; Costa IM; Biasoto HP; Lima GM; Silva C; Pessoa A; Monteiro G
Blood Rev; 2020 Sep; 43():100651. PubMed ID: 32014342
[TBL] [Abstract][Full Text] [Related]
36. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
Maese L; Rizzari C; Coleman R; Power A; van der Sluis I; Rau RE
Pediatr Blood Cancer; 2021 Oct; 68(10):e29169. PubMed ID: 34105243
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
38. Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.
Shishparenok AN; Gladilina YA; Zhdanov DD
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894901
[TBL] [Abstract][Full Text] [Related]
39. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
40. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
